- Home
- GNTA vs BOLD Comparison
GNTA vs BOLD Comparison
Compare GNTA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- BOLD
- Stock Information
- Founded
- GNTA 2014
- BOLD 2018
- Country
- GNTA Italy
- BOLD United States
- Employees
- GNTA N/A
- BOLD N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- BOLD
- Sector
- GNTA Health Care
- BOLD
- Exchange
- GNTA Nasdaq
- BOLD Nasdaq
- Market Cap
- GNTA 67.4M
- BOLD 81.0M
- IPO Year
- GNTA 2021
- BOLD 2024
- Fundamental
- Price
- GNTA $5.34
- BOLD $2.95
- Analyst Decision
- GNTA Strong Buy
- BOLD Strong Buy
- Analyst Count
- GNTA 1
- BOLD 3
- Target Price
- GNTA $25.00
- BOLD $23.00
- AVG Volume (30 Days)
- GNTA 28.4K
- BOLD 57.8K
- Earning Date
- GNTA 01-01-0001
- BOLD 11-11-2024
- Dividend Yield
- GNTA N/A
- BOLD N/A
- EPS Growth
- GNTA N/A
- BOLD N/A
- EPS
- GNTA N/A
- BOLD N/A
- Revenue
- GNTA N/A
- BOLD N/A
- Revenue This Year
- GNTA N/A
- BOLD N/A
- Revenue Next Year
- GNTA N/A
- BOLD N/A
- P/E Ratio
- GNTA N/A
- BOLD N/A
- Revenue Growth
- GNTA N/A
- BOLD N/A
- 52 Week Low
- GNTA $2.20
- BOLD $2.82
- 52 Week High
- GNTA $7.28
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- BOLD N/A
- Support Level
- GNTA $4.89
- BOLD N/A
- Resistance Level
- GNTA $6.20
- BOLD N/A
- Average True Range (ATR)
- GNTA 0.70
- BOLD 0.00
- MACD
- GNTA -0.06
- BOLD 0.00
- Stochastic Oscillator
- GNTA 37.32
- BOLD 0.00
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.